Sutro Biopharma’s (STRO) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Sutro Biopharma (NASDAQ:STRO) in a report issued on Monday,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock. HC Wainwright also issued estimates for Sutro Biopharma’s Q4 2024 earnings at ($0.68) EPS, FY2024 earnings at ($2.75) EPS, Q1 2025 earnings at ($0.82) EPS, Q2 2025 earnings at ($0.87) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.57) EPS, FY2026 earnings at ($3.52) EPS, FY2027 earnings at ($3.47) EPS and FY2028 earnings at ($3.03) EPS.

Several other equities analysts also recently commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a research report on Monday, September 16th. Piper Sandler restated an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a research note on Friday, October 11th. Finally, Truist Financial reduced their price objective on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $12.14.

Sutro Biopharma Trading Down 1.1 %

Shares of NASDAQ STRO opened at $2.67 on Monday. The firm has a 50-day moving average of $3.64 and a two-hundred day moving average of $3.81. Sutro Biopharma has a twelve month low of $2.13 and a twelve month high of $6.13. The company has a market capitalization of $220.17 million, a price-to-earnings ratio of -1.66 and a beta of 1.17.

Institutional Investors Weigh In On Sutro Biopharma

A number of large investors have recently made changes to their positions in the business. Point72 Asset Management L.P. increased its stake in shares of Sutro Biopharma by 1,606.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 4,447,634 shares of the company’s stock valued at $13,032,000 after purchasing an additional 4,186,938 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Sutro Biopharma by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock worth $17,079,000 after buying an additional 132,790 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Sutro Biopharma by 7.7% in the third quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after purchasing an additional 132,015 shares during the period. State Street Corp boosted its holdings in Sutro Biopharma by 5.2% during the third quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after buying an additional 81,855 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Sutro Biopharma by 30.8% in the 2nd quarter. Acadian Asset Management LLC now owns 1,574,958 shares of the company’s stock worth $4,613,000 after buying an additional 370,705 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.